Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181948 · ClinicalTrials.gov registry record · Phase 4
Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00181948: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00181948 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181948, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This will be a 6-week, unblinded study using the medication Strattera for children and adolescents with attention deficit hyperactivity disorder (ADHD) who failed to respond to an adequate trial of stimulant treatment. Specific hypotheses are as follows: Hypothesis 1: ADHD symptomatology in youth with ADHD will be responsive to Strattera treatment in the short term. Hypothesis 2: Strattera treatment (in doses of up to 120 mg/day or 1.2 mg/kg/day) in children and adolescents with ADHD will be safe and well tolerated.
Interventions
- DRUG atomoxetine (Strattera)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
What the finished NCT00181948 record still lists
NCT00181948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which atomoxetine (Strattera) is the first listed.
NCT00181948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00181948 about?
NCT00181948 is a clinical study titled "Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy". This will be a 6-week, unblinded study using the medication Strattera for children and adolescents with attention deficit hyperactivity disorder (ADHD) who failed to respond to an adequate trial of stimulant treatment. Specific hypotheses are as follows: Hypothesis 1: ADHD symptomatology in youth w...
What is the current status of trial NCT00181948?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2004-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00181948?
The interventions under investigation include: atomoxetine (Strattera) (DRUG).
Who is sponsoring clinical trial NCT00181948?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00181948's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia